DermACELL AWM®
Human Acellular Dermal Matrix (hADM)

Clinical Overview

Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matracell®, a proprietary, patented, and validated processing technology. Matracell removes a minimum of 97% of donor DNA[1], allowing for rapid cellular infiltration and re-vascularization.[2] Dermacell AWM is terminally sterilized, ready to use without refrigeration or re-hydration.[3]

Clinical Applications

Diabetic foot ulcers (DFUs), venous leg ulcers, dehisced surgical wounds, traumatic burns

Why Use

Biohospitable: To potentially minimize any adverse patient responses, no visible cells remain and ≥ 97% of donor DNA is removed.[1]

Intact Acellular Framework: Retains native growth factors, collagen and elastin.[4,5]

Room Temperature Storage: Ready to use out of the package (15°C- 30°C)

Strength: Pull-out strength and load to failure are comparable to native dermis.[6,7]

Sterile: Sterilized to a Sterility Assurance Level (SAL) of 10^{-6}, medical device grade sterility.[8]

Structural Support: Facilitates use with sutures and staples.

Proven: Conducted the largest randomized controlled trial (RCT) to date using hADM in chronic wounds.[9]

FOR USE IN INDIA

**North America**
1.888.847.7831
orders@lifenethealth.org

Europe
+ 43 1 375002710
eu_orders@lifenethealth.eu

Latin America □ Asia □ Middle East
1.757.464.4761 ext. 2000
internat.orders@lifenethealth.org

www.LifeNetHealth.org
www.LifeNetHealth.eu

DermACELL AWM®
Advanced Decellularized Dermis

	THICKNESS	SIZE	SHELF LIFE	ORDER CODE	STORAGE
Unmeshed	0.2 - 1.00 mm	2 x 2 cm	3 years	DCELL100	Room Temperature Ready-to-use (15°C to 30°C)
		4 x 4 cm	3 years	DCELL101	
		5 x 7 cm	3 years	DCELL102	
		6 x 7 cm	3 years	DCELL103	
		4 x 8 cm	3 years	DCELL104	
		2 x 2 cm	3 years	DCELL110	
Meshed / Meshed at a 1.5:1 ratio		3 X 3 cm	3 years	DCELL111	
		4 x 4 cm	3 years	DCELL112	
		5 X 7 cm	3 years	DCELL152	
		6 X 7 cm	3 years	DCELL153	
		4 x 8 cm	3 years	DCELL154	
		5 x 9 cm	3 years	DCELL155	

References

1. LifeNet Health 10-006, Process PQ, Devitalization of Dermal Allografts.
2. Capito AE, Tholpady SS, Agrawal H, Drake DB, Katz AJ. Evaluation of host tissue integration, revascularization, and cellular infiltration within various dermal substrates. Ann Plast Surg. 2012 May;68(5):495-500.
3. Moore MA, Samsell B, Wallis G, et al. Decellularization of human dermis using non-denaturing anionic detergent and endonuclease: a review. Cell Tissue Bank. 2015; 16(2):249-259. https://doi.org/10.1007/s10561-014-9467-4
4. 68-20-047, Analysis of the Acellular Matrix, Growth Factors, and Cytokines Present in Oracell.
5. LifeNet Health, TR 0292, LifeNet Health's Decellularized Dermis, Dermacell, Comparison to the USP Monograph, Scaffold Human Dermis.
6. LifeNet Health TR-0119, Assessment of the Impact of Glycerol Treatment and Gamma Irradiation on the Uniaxial Tensile Strength of Acellular Dermis.
7. LifeNet Health TR-0148, A Preliminary Evaluation of the Suture Retention Strength of Acellular Dermis.
8. LifeNet Health 10-008, Process, PQ, Method 2B Terminal Sterilization Validation for the Devitalized Dermis Allografts Family.
9. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017.

FOR USE IN INDIA

LifeNet Health® Biologics

North America
1.888.847.7831
orders@lifenethealth.org

Europe
+ 43 1 375002710
eu_orders@lifenethealth.eu

Latin America □ Asia □ Middle East
1.757.464.4761 ext. 2000
internat.orders@lifenethealth.org

www.LifeNetHealth.org
www.LifeNetHealth.eu